PMEDAP is a potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality and an inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP also has anti-murine cytomegalovirus (MCMV) activity.

β-Lipotropin (88-91)

FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.